Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associa
Clinical trials using JAKi in Graft-versus-Host-Disease according to... | Download Scientific Diagram
Itacitinib Clinical Trials for Chronic and Acute GVHD
Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases - ScienceDirect
Clinical trials using JAKi in Graft-versus-Host-Disease according to... | Download Scientific Diagram
Itacitinib | C26H23F4N9O - PubChem
PDF) The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib
Cancers | Free Full-Text | Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies? | HTML
Ongoing clinical trials of PD-1/PD-L1 immunotherapeutics in breast cancer | Download Table
![PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/265b8d3517575964e518b92944c9558171cdf15d/8-Table2-1.png "PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar")
PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar
![PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/265b8d3517575964e518b92944c9558171cdf15d/10-Figure1-1.png "PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar")
PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar
Frontiers | New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions | Immunology
Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases - ScienceDirect
Itacitinib (INCB039110) | JAK1 Inhibitor | MedChemExpress
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study | Journal for ImmunoTherapy of Cancer
Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials | Immunotherapy
Incyte's Graft-Versus-Host Trial Fails to Meet Primary Endpoint | BioSpace
,%20Cytokine%20Release%20Syndrome,%20Acute%20Myeloid%20Leukemia%20(AML),%20Precursor%20Cell%20Lymphoblastic%20Leukemia-Lymphoma,%20Leukemia,%20Acute%20Lymphoblastic%20Leukemia%20(ALL),%20Graft%20vs%20Host%20Disease:%0A%0AItacitinib%20for%20Graft%20vs%20Host%20Disease.png?md=1 "Itacitinib for Graft vs Host Disease Clinical Trial | Power")
Itacitinib for Graft vs Host Disease Clinical Trial | Power
Itacitinib prevents xenogeneic GVHD in humanized mice | Bone Marrow Transplantation
Completed and ongoing clinical trials assessing STAT3 pathway... | Download Scientific Diagram
Itacitinib adipate | C32H33F4N9O5 - PubChem
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial - The Lancet Haematology
![PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/265b8d3517575964e518b92944c9558171cdf15d/7-Table1-1.png "PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar")
PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease - ScienceDirect
Incyte sinks as itacitinib fails pivotal test in acute GVHD | Fierce Biotech
Clinical Trials of Itacitinib for Chronic and Acute GVHD
![PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/265b8d3517575964e518b92944c9558171cdf15d/6-Table1-1.png "PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar")
PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar
